The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma.
and form their own flora (ie microbiomes) in individual organs. The gut microbiota appears haphazard in infants, but begins resembling the adult microbiome by age 3 years. Nevertheless, the microbial distribution from the esophagus to the rectum varies spatially and temporally throughout the individual's lifespan. The normal gut microbiota carries out specific functions in host nutrient metabolism, xenobiotic and drug metabolism, structural integrity maintenance of the gut mucosal barrier, immunomodulation, and protection against pathogens. [11] [12] [13] [14] [15] Recently, the gut microbiome has been shown to play a crucial role in health, as well as in diseases such as obesity, 16 inflammatory bowel disease, 17, 18 diabetes, 19, 20 non-alcoholic fatty liver disease, [21] [22] [23] and several types of cancers. 24, 25 Experimental evidence indicates that the human intestinal microbiome can influence tumor development and progression in the gastrointestinal tract by damaging DNA, activating oncogenic signaling pathways, producing tumor-promoting metabolites, and suppressing the antitumor immune response. 7, [25] [26] [27] [28] [29] As the gastrointestinal microbiota can be modified through the rational deployment of antibiotics, probiotics, and prebiotics, [30] [31] [32] The present review discusses current knowledge on the relationship between the microbiome and esophageal cancer. Importantly, because two histological types (adenocarcinoma and squamous cell carcinoma) present as different diseases in terms of their epidemiology, pathogenesis, and tumor biology, the role of the microbiome is discussed separately for each histological type.
| MICROBIOME OF THE NORMAL ESOPHAGUS
Distribution of the gut microbiota varies temporally and spatially at the genus level and higher. From the oral cavity, through the esophagus and distally to the rectum, the diversity and number of bacteria changes markedly, ranging from 10 1 per gram of contents in the esophagus and stomach to 10 12 per gram of contents in the colon and distal gut. 33 Importantly, the esophagus, unlike other luminal organs of the digestive system, does not retain food contents.
In the 1990s, microbiological studies depended mainly on conventional bacterial culture-based methods. These studies demonstrated that the esophagus is either sterile or contains only a few transient microbes swallowed from the oropharynx or ejected from the stomach by gastroesophageal reflux. 34 Gagliardi et al. 34 revealed that Streptococcus viridans is the most frequent microorganism in both the normal esophagus and the oropharynx. These findings were consolidated by Norder Grusell et al., 35 who collected brush samples and biopsy samples from the esophagus, and reported the occurrence rate of Streptococcus viridans as 95-98%. These studies support a possible correlation between the flora in the oropharynx and the esophagus. However, as most of the autochthonic esophageal microbiome is viable but non-culturable, it will likely be missed by standard culturing methods. More recently, the diversity of the non-culturable microbiota has been characterized by advanced approaches such as polymerase chain reaction (PCR) of 16S ribosomal RNA. 36 
| MICROBIOME IN E SOPHAGITIS AND BARRETT' S ESOPHAGUS
Gastroesophageal reflux disease (GERD) is an important risk factor for esophageal adenocarcinoma. GERD can lead to erosive esophagitis and (after an aberrant healing process) to a metaplastic, specialized intestinal epithelium (ie Barrett's esophagus). 38 Among the 6-14% of GERD patients who develop Barrett's esophagus, 0.5-1% will progress to adenocarcinoma. 39 In a meta-analysis of population-based studies, weekly symptoms of GERD were estimated to increase the risk of esophageal adenocarcinoma approximately fivefold. 40 Several studies have documented microbiome status in esophagitis and Barrett's esophagus. In a microscopic study of Barret's esophageal biopsy specimens, Osias et al. 41 found that cultivable bacteria were closely associated with the mucosa of the specimens.
They concluded that Barrett's mucosa are colonized rather than transiently visited by resident bacteria. Macfarlane et al. 42 isolated a broader range of bacteria from patients with Barrett's esophagus than from individuals without Barrett's esophagus, suggesting a higher microbiological diversity in patients with Barrett's esophagus.
Using 16S rDNA sequencing technology, Yang et al. 43 Using culture-independent techniques, Liu et al. 44 examined the bacterial composition at the 16S rDNA gene site in subjects with a normal esophagus, reflux esophagitis, or Barrett's esophagus. Veillonella, Prevotella, Neisseria, and Fusobacterium prevailed in patients with reflux esophagitis and Barrett's esophagus, but were not detected in normal esophagus. More recently, Gall et al. 45 showed that Streptococcus and Prevotella dominate the esophageal microbiota of Barrett's esophagus patients, with no substantial intraindividual differences between normal and metaplastic esophageal mucosa.
They also found a significant association between the Streptococcus/ Prevotella ratio and some important risk factors for Barrett's esophagus and esophageal adenocarcinoma (eg waist-to-hip ratio, hiatal hernia length). Overall, the esophageal bacteria differ among normal esophagus, reflux esophagitis and Barrett's esophagus, supporting that esophageal disease is related to the bacterial community profile, possibly through the innate immune system. Gram-negative organisms, which predominate in reflux esophagitis and Barrett's esophagus, produce specific constituents such as lipopolysaccharide (LPS)
that activate the innate immune responses. 46 Either directly or indirectly, LPS may stimulate the innate immune system's Toll-like receptor (TLR) 4 in the epithelial or inflammatory cells, leading to nuclear factor kappa B (NF-jB) activation. Increased NF-jB activation is associated with elevated levels of inflammatory cytokines. 47 Activation of the NF-jB pathway increases stepwise along the spectrum of reflux esophagitis, Barrett epithelium, and adenocarcinoma, paralleling the increases in interleukin (IL)-1b, IL-6, IL-8, and tumor necrosis factor (TNF)-a. [48] [49] [50] Taken together, in reflux esophagitis and Barrett's esophagus, the change of microbiomes (ie increased
Gram-negative organisms) may contribute to esophageal adenocarcinoma by inducing chronic inflammation, triggering a cascade that leads to adenocarcinoma. 46 4 | MICROBIOME AND ESOPHAGEAL
ADE NOCARCINOMA
Given the important role of the gut microbiome in human malignancies, a better understanding of the microbiome in esophageal cancer is increasingly important. In the 1980s, culture-based methods and surgically resected specimens of esophageal adenocarcinoma and squamous cell carcinoma revealed the same microbiota in normal and cancerous tissues. However, these studies were focused on identifying pathogens related to postoperative infections, rather than comparing the non-pathogenic bacteria in esophageal cancer cases and control cases. [51] [52] [53] More recently, Narikiyo et al. 54 characterized the microbiota of normal and cancerous esophageal tissue by 16S sequencing technology. Cancerous tissues were obtained from 20 patients undergoing surgical resection for esophageal cancer. Both microbiota were consistently dominated by the oral periodontopathic spirochete Treponema denticola, Streptococcus mitis, and Streptococcus anginosus, but the pathological subtypes of the tumors were not specified. 54 Using a mixed culture-dependent and culture-independent approach, Blackett et al. 55 compared the microbiota in refluxasymptomatic controls and in patients with GERD, Barrett's esophagus, and esophageal adenocarcinoma. Campylobacter were significantly more enriched in GERD and Barrett's esophagus than in the controls and esophageal adenocarcinoma. In addition, cytokines associated with carcinogenesis (eg IL-18) were more highly expressed in the tissues colonized by Campylobacter. 55 Given the potential human pathogenicity of Campylobacter species (which has been recently recognized), 56 the role of Campylobacter in esophageal adenocarcinoma progression might mimic that of Helicobacter pylori in gastric cancer.
The relationship between the microbiome and esophageal adenocarcinoma development has been experimentally investigated.
Sawada et al. 57 investigated whether altering the microbiome with antibiotics affected the development of esophageal adenocarcinoma in a rat model with esophagojejunostomy. Terminal restriction fragment length polymorphism analysis showed that the esophageal microbiomes differed between the two groups; for instance, the proportions of Lactobacillales and Clostridium were reduced and elevated in the antibiotics group, respectively. However, the altered microbiome did not affect the incidence of esophageal adenocarcinoma. In a rat model with esophagojejunal anastomosis, Zaidi et al. 58 revealed a prevalence of Escherichia coli in Barrett's esophagus and esophageal adenocarcinoma; moreover, TLR 1-3, 6, 7 and 9 were significantly upregulated in esophageal adenocarcinoma compared with normal epithelium. This suggests an association between the TLR signaling pathway and E. coli, hinting that early molecular changes are mediated by microbes in the rat model of esophageal adenocarcinoma carcinogenesis. 58 At this time, less conclusive information is available about the effects of the microbiome on esophageal adenocarcinoma. Nonetheless, alteration of microbiome status is potentially involved in the progression of GERD and Barrett's esophagus toward adenocarcinoma.
| MICR OBIOME AN D ESOPHAGE AL SQUAMOUS CELL CARCINOMA
The microbiome is less well characterized in esophageal squamous cell carcinoma than in esophageal adenocarcinoma. 59 Yu et al.
60
F I G U R E 1 Microbiome status of normal esophagus, reflux esophagitis, and Barrett's esophagus. In the human distal esophagus, inflammation and intestinal metaplasia are associated with global alteration of the microbiome 43 BABA ET AL.
| 101 observed a negative correlation between esophageal microbial richness and esophageal squamous dysplasia (the precursor lesion of esophageal squamous cell carcinoma) in a human oral microbe identification microarray. They suggested that individuals with lower esophageal microbial complexity are more prone to developing esophageal squamous dysplasia. 60 Another study using 16S rDNA sequencing technology demonstrated that, relative to controls, the gastric corpus microbiota of patients affected by esophageal squamous dysplasia and esophageal squamous cell carcinoma are enriched in Clostridiales and Erysipelotrichales, suggesting that gastric dysbiosis is involved in the progression from esophageal squamous dysplasia to squamous cell carcinoma. 61 Gao et al. 62 populations. Second, the microbiota's potential ability to modulate the toxicity and efficacy of chemotherapy has also attracted interest. 66 For example, the microbiota and immune system have reportedly enhanced the efficacy of oxaliplatin, a platinum-based anticancer drug that treats esophageal cancer. 67 Gut microbiota stimulate the production of reactive oxygen species (ROS) by immune cells. ROS enhance the DNA damage caused by oxaliplatin, blocking DNA replication and transcription and resulting in cell death. 67 Third, given the intertwined nature of the microbiota and the immune system, microbiota likely influence their host's responsiveness to immunotherapy. Immunotherapy (eg antibodies to PD-L1) ranks among the most exciting and successful developments in F I G U R E 2 Clinical implication of the gut microbiome in human cancers cancer care over the past decade. Antibiotic-mediated disruption of the microbiota impaired the effectiveness of CpG oligonucleotide immunotherapy in mice with subcutaneous tumors. 25, 67 Fourth, the microbiota is a potential biomarker of diagnosis or clinical outcome.
If correct, the relationship between Fusobacterium nucleatum and poor clinical outcome identified in our previous work will have clinical implications. 
